Critical elements in the development of cell therapy potency assays for ischemic conditions.
A successful potency assay for a cell therapy product (CTP) used in the treatment of ischemic conditions should quantitatively measure relevant biological properties that predict therapeutic activity. This is especially challenging because of numerous degrees of complexity stemming from factors that include a multifactorial complex mechanism of action, cell source, inherent cell characteristics, culture method, administration mode and the in vivo conditions to which the cells are exposed. The expected biological function of a CTP encompasses complex interactions that range from a biochemical, metabolic or immunological activity to structural replacement of damaged tissue or organ. Therefore, the requirements for full characterization of the active substance with respect to biological function could be taxing. Moreover, the specific mechanism of action is often difficult to pinpoint to a specific molecular entity; rather, it is more dependent on the functionality of the cellular components acting in a in a multifactorial fashion. In the case of ischemic conditions, the cell therapy mechanism of action can vary from angiogenesis, vasculogenesis and arteriogenesis that may activate different pathways and clinical outcomes. The CTP cellular attributes with relation to the suggested mechanism of action can be used for the development of quantitative and reproducible analytical potency assays. CTPs selected and released on the basis of such potency assays should have the highest probability of providing meaningful clinical benefit for patients. This White Paper will discuss and give examples for key elements in the development of a potency assay for treatment of ischemic disorders treated by the use of CTPs.
BioGenCell Ltd, Hematology BGC Stem Cell Research, Sanz Medical Center Laniado Hospital, Netanya, Israel.
Yael
Y
Porat
Lonza, Walkersville, Maryland, USA.
Eytan
E
Abraham
Pluristem, MATAM, Haifa, Israel.
Ohad
O
Karnieli
Pluristem, MATAM, Haifa, Israel.
Sagi
S
Nahum
Juventas Therapeutics, Cleveland, Ohio, USA.
Juliana
J
Woda
Akron Biotech, Boca Raton, Florida, USA. Electronic address: czylberberg@akronbiotech.com.
Claudia
C
Zylberberg
D001681:Biological Assay / Q000379:methods*; D064987:Cell- and Tissue-Based Therapy / Q000379:methods*; D006801:Humans; D007511:Ischemia / Q000175:diagnosis / Q000628:therapy*; D018919:Neovascularization, Physiologic / Q000502:physiology
angiogenesis; cell therapy; potency assay; vasculogenesis